Drug reference

Atezolizumab

Monoclonal Antibody · Antineoplastic

Monoclonal AntibodyAntineoplastic

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

and reproductive

FDA category + note

Top interactionssee all 12 →

AdalimumabSevereDatabaseDDInter
BaricitinibSevereDatabaseDDInter
CertolizumabSevereDatabaseDDInter
CladribineSevereDatabaseDDInter

Mechanism

Atezolizumab is a monoclonal antibody, which binds to the programmed death-ligand 1 (PD-L1), thereby reactivating the immune response to tumour cells.

Indications

Urothelial carcinoma (specialist use only)Non-small cell lung cancer (specialist use only)Small cell lung cancer (specialist use only)Breast cancer (specialist use only)Metastatic melanomaNon–small cell lung cancerRenal cell carcinomaHead and neck cancers (clinical trials)Breast cancer (clinical trials)Small cell lung cancer (clinical trials)Hodgkin lymphoma (clinical trials)Gastric cancer (clinical trials)Hepatocellular carcinoma (clinical trials)Bladder cancer (clinical trials)Ovarian cancer (clinical trials)Colon cancer (clinical trials)Merkel cell carcinoma (clinical trials)cancer therapyurothelial cancerNSCLCsmall cell lung cancer (with carboplatin and etoposide)triple-negative breast cancer (with paclitaxel)hepatocellular carcinoma (with bevacizumab)melanoma (with cobimetinib and vemurafenib)

Dosing

Adult: l INDICATIONS AND DOSE Urothelial carcinoma (specialist use only) | Non-small cell lung cancer (specialist use only) | Small cell lung cancer (specialist use only) | Breast cancer (specialist use only) ▶ BY INTRAVENOUS INFUSION ▶ Adult: (consult product literature) Abnormal thyroid function—manufacturer advises to consider appropriate treatment .…

Pharmacokinetics

Half-life

27 days

Side effects

Common

Abdominal painappetite decreasedarthralgiaascitesastheniachillscoughcystitiscytokine release syndromediarrhoeadysphagiadyspnoeaelectrolyte imbalanceeuthyroid sick syndromeeye disordersfevergastrointestinal disordersgoitrehepatic disordershyperglycaemiahypersensitivityhypotensionhypothyroidismhypoxiaincreased risk of infectioninﬂuenza like illnessinfusion related reactionmyalgiamyxoedemanasal congestionnauseaoesophageal varicesoesophageal varices haemorrhageoropharyngeal complaintspainradiation pneumonitisrespiratory disordersskin reactionsskin ulcerthroat irritationthrombocytopeniathyroid disorderfatiguedecreased appetitedyspneamusculoskeletal painconstipationurinary tract infection (in urothelial carcinoma patients)

Serious

Immune-related adverse events (hepatitis, pneumonitis, colitis, rash, vitiligo, endocrine pathology)
immune-related hepatitis
colitis
hypophysitis
thyroid disorders
adrenal insufficiency
type 1 diabetes mellitus (rarely)
pancreatitis
myasthenia gravis
Guillain-Barré syndrome
ocular inflammation